HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.

Abstract
The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age=56.8 years; median KPS=90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.
AuthorsMaria Grazia Fabrini, Giovanni Silvano, Ivan Lolli, Franco Perrone, Annarita Marsella, Valerio Scotti, Luca Cionini
JournalJournal of neuro-oncology (J Neurooncol) Vol. 92 Issue 1 Pg. 79-86 (Mar 2009) ISSN: 0167-594X [Print] United States
PMID19018476 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents
  • Nitrosourea Compounds
  • Organophosphorus Compounds
  • fotemustine
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Brain Neoplasms (drug therapy, mortality)
  • Disease-Free Survival
  • Female
  • Glioblastoma (drug therapy, mortality)
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Nitrosourea Compounds (therapeutic use)
  • Organophosphorus Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: